Spyre Therapeutics, Inc. - SYRE
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL MANAGEMENT, LLC | 2.4% | 1,892,200 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | KEVIN TANG | 2.4% | 1,892,200 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS, LP | 1.3% | 1,012,338 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS INTERNATIONAL, LP | 1.1% | 879,862 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS III, INC | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TANG CAPITAL PARTNERS IV, INC | 0.0% | 0 | View |
| Oct 17, 2025 | SCHEDULE 13D/A | — | 9.99% | — | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.